SGLT2 Inhibitors in Combination Therapies for Tumors: A Novel Approach to Synergistic Treatment Strategies

Hao Su, Xiangyu Li, Shurong Wang, Xuping Yang, Longyang Jiang, Hengli Luo, Yaping Li, Jie Zhou, Yilan Huang, Min Li · 2025

Read SGLT2 Inhibitors in Combination Therapies for Tumors: A Novel Approach to Synergistic Treatment Strategies by Hao Su, Xiangyu Li, Shurong Wang, Xuping Yang, Longyang Jiang, Hengli Luo, Yaping Li, Jie Zhou, Yilan Huang, Min Li (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12751339.txt.

Description

Su leads a team reviewing diabetes drugs called SGLT2 inhibitors as partners in cancer treatment in a 2025 paper. These drugs were built for blood sugar control in type 2 diabetes. Lab work suggests they can also slow tumor growth.

Proposed routes include rewiring tumor metabolism, cutting glucose uptake, and reshaping the tumor surroundings. Trials now test the drugs alongside chemotherapy, immunotherapy, and targeted therapy. Early studies focus on tumor shrinkage, spread, and better outcomes. The review argues combinations could beat the limits of single-drug treatment. Matching regimens to patients could personalize care. The authors frame the class as an emerging add-on, with proof still developing. Clinical evidence remains early.

Catalog record

CREATORHao Su, Xiangyu Li, Shurong Wang, Xuping Yang, Longyang Jiang, Hengli Luo, Yaping Li, Jie Zhou, Yilan Huang, Min Li
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE104 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12751339

Browse the full library · About the Tower of Babel